Home/ Stocks/ GTBP

GT Biopharma Inc. Common Stock

GTBP XNAS

$0.32 +0.03 (+9.47%) ▲ 15-min delayed

Open

$0.30

High

$0.33

Low

$0.30

Volume

570.9K

Market Cap

$10.85M

About GT Biopharma Inc. Common Stock

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 1 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$-861,000	$-2,833,000	$-0.11
FY 2025	N/A	$-28,354,000	$-6.68
Q3 2025	N/A	$8.30M	$1.04
Q2 2025	N/A	$-30,169,000	$-10.92

Related Market News

No specific coverage for GTBP yet. Check out our latest market news or earnings calendar.

Get GTBP Alerts

Stay ahead with breaking news, price alerts, and expert analysis on GT Biopharma Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.